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Abstract
Background: Gastroesophageal reflux disease is a common and chronic disorder but long term,
prospective studies of the fate of patients seeking medical advice are scarce. This is especially
prominent when looking at non-erosive reflux disease (NERD) patients.
Methods: We designed a prospective cohort to assess the long term outcome of GERD patients
referring to gastroenterologists. Consecutive consenting patients, 15 years of age and older,
presenting with symptoms suggestive of GERD referring to our outpatient clinics undergo a 30
minute interview. Upper gastrointestinal endoscopy is performed for them with protocol biopsies
and blood samples are drawn. Patients are then treated according to a set protocol and followed
regularly either in person or by telephone for at least 10 years.
Discussion: Our data show that such a study is feasible and follow-ups, which are the main
concern, can be done in a fairly reliable way to collect data. The results of this study will help to
clarify the course of various subgroups of GERD patients after coming to medical attention and
their response to treatment considering different variables. In addition, the basic symptoms and
biological database will fuel further molecular epidemiologic studies.
Background
Gastro-esophageal reflux disease (GERD) is a common
and chronic problem [1]. The west has faced a dramatical
increment in the incidence and prevalence of the disease
over the past couple of decades [2,3]. Recent reports from
developing countries indicate a similar trend [3-5]. In
addition to imposing a large financial burden on the
health care system, GERD affects different aspects of the
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patients' health including their quality of lives [6,7].
Therefore, it has received extensive attention during the
past two decades. Conventionally, endoscopy is used to
make the diagnosis, look for complications (e.g. Barrett's
esophagus, strictures, ulcers, and adenocarcinoma) and
rule out concomitant benign or malignant diseases [8].
Finding endoscopic esophagitis secures the diagnosis and
its healing is commonly used as an endpoint for success-
ful treatment. In a recent endoscopic survey in Iran, about
37% of the population had endoscopic esophagitis [9].
GERD patients are a heterogeneous group. They may be
categorized considering their symptoms and endoscopic
findings. From an endoscopic point of view, GERD is clas-
sified as those with no recognizable esophageal erosion
(non erosive reflux disease, NERD), those with visible dis-
tal esophageal erosions (erosive reflux disease, ERD), and
those with columnar metaplasia in the distal esophagus
(Barrett's esophagus, BE). Occurrence of symptoms is not
predictable by endoscopic findings, but it appears to be
influenced by age, body mass index (BMI), alcohol, and
cigarette use [[3,10], and [11]]. However, our knowledge
about the differences in risk factors for NERD, ERD, and
BE is very little. Neither typical symptoms nor amount of
acid exposure of the esophageal mucosa can adequately
predict the occurrence and severity of esophagitis [12-15].
It has been shown that long-lasting GERD symptoms can
be a risk factor for BE [16,17]. Patients who develop BE
may have an increased risk of esophageal adenocarci-
noma. Adenocarcinoma has been reported in up to 10%
of patients with BE at the time of the first upper endos-
copy [18].
Large prospective studies will improve our understanding
of the epidemiology, natural history, and complications
of GERD [19]. There have been a few endoscopy-based
cohorts with a follow-up period of more than twelve
months [20-22]. Hereby we describe the methodology of
our study aimed at following a cohort of 1,200 GERD
patients for at least 10 years.
Objectives
The primary objective of this ongoing study is to deter-
mine the response of GERD patients to medical therapy,
factors influencing their response, assess interaction
between various clinical and demographic features and
the need for maintenance therapy. Secondary objectives
include evaluation of (1) course of the disease in patients
after consulting a physician, (2) factors affecting regres-
sion and relapse of GERD related symptoms, (3) the asso-
ciation between various risk factors and the progression of
GERD and BE, (4) the socioeconomic costs of the disease,
(5) the relationship between Helicobacter pylori infection
and its eradication and GERD, (6) the interaction between
genetic factors, serologic and histologic findings and the
course of GERD.
Therefore, we developed a database of GERD patients to
observe their overall outcomes and assess risk factors,
diagnostic and therapeutic methods as they develop, and
the health related quality of life of different subgroups
described above before and after treatment. Other goals of
the study are assessing the difference in severity of symp-
toms, responding to treatment, and the need for mainte-
nance therapy in the following subgroups: patients with
erosive reflux and non-erosive reflux disease (ERD vs.
NERD), different grades of esophagitis, different present-
ing esophageal symptoms, and patients with esophageal
and extra-esophageal symptoms. We also assess the differ-
ence in responding to medical treatment and the need for
maintenance therapy between patients in whom helico-
bacter pylori (HP) has been eradicated for other indica-
tions and those who are still HP positive. In addition, the
relation between cytochrome P-450 (e.g. CYP-450-IIC19)
polymorphism and response to treatment and the need
for maintenance therapy are assessed. We will also deter-
mine the frequency of other concomitant GI and non-GI
disorders among the patients in the cohort especially that
of irritable bowel syndrome (IBS), the metabolic syn-
drome (MES) and peptic ulcer disease (PUD).
Methods/Design
Study design
The Prospective Acid Reflux Study of Iran (PARSI) is a pro-
spective study being conducted in Tehran, Iran in which
patients with symptoms suggestive of GERD are followed
prospectively in a set protocol for at least 10 years.
The patients are not paid for participation in the study.
Any evaluation which is not part of the routine clinical
care of these patients will be covered totally by the inves-
tigators and the Digestive Disease Research Center
(DDRC) of Tehran University of Medical Sciences
(TUMS). The study has been approved by the ethics com-
mittee of TUMS and is in accord with the declaration of
Helsinki. All patients provide written informed consent
before enrollment. Not giving an informed consent does
not prevent the patient from receiving quality clinical
care.
Educational sessions were provided for the investigators
to assure standardization of the procedures, interviews
and conducting the study.
Patients
All consenting patients, 15 years of age and older, present-
ing with symptoms suggestive of GERD referring to our
outpatient clinics (Behrouz and Iran-e-ma) undergo a 30
minute interview; this is done by a trained general practi-BMC Gastroenterology 2007, 7:42 http://www.biomedcentral.com/1471-230X/7/42
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tioner. All patients who have major symptoms (Table 1)
for at least 4 weeks over the past three months are
enrolled. Those presenting by minor symptoms (Table 1)
are eligible if they have a positive omeprazole test (subsid-
ence of symptoms by omeprazole 20 mg orally twice daily
for 4 weeks) or have erosions on endoscopy. Exclusion cri-
teria are shown in Table 2. Study flow chart is shown in
Figure 1.
Demographic and medical questionnaires
At the baseline visit, each participant's medical history
including information on frequency, severity, and inten-
sity of major and minor GERD symptoms, duration of the
symptoms, chief complaint taking him/her to the physi-
cian, coffee, tea and alcohol consumption, and up to five
specific foods which exacerbate their symptoms are
recorded. Another questionnaire including demographic
data (age, sex, place and date of birth, job, marital status,
education, weight, height, income status), habits [exer-
cise, smoking, opium use, the interval between having
dinner to going to bed (dinner to bed time), sleep posi-
tion, and alcohol intake], past medical history (any
comorbid diseases or surgeries and type of delivery in
females), family history (any problem with their upper GI
tract in first degree family members and spouse), and drug
history is also filled out. Average salt intake is estimated
through dietary habit assessment.
Blood samples
Twelve milliliters of venous blood is taken before upper
GI endoscopy. Both EDTA and clot aliquots are prepared
and kept in -70°C freezers for further analysis.
Endoscopy and biopsies
Upper GI endoscopy is performed in a left lateral position
with local anesthesia ± intravenous midazolam according
to patients' need and preference. Structural and mucosal
details of the esophagus, stomach, and duodenum down
to its second portion are recorded. Esophagitis is recorded
using the Los Angeles classification [23]. Routine antral
biopsy for rapid urease test (RUT) is taken and all lesions
needing biopsy, as judged by the endoscopist, are biop-
sied. Thereafter, protocol biopsies (Figure 2) are taken.
Biopsies are fixed in 10% buffered formalin; standard 4
micrometer thick sections are prepared and stained with
hematoxilin and eosin (H & E). The Sydney system is used
for interpretation of gastric biopsies [24].
Treatment protocol
A step down protocol is used for treatment. Omeprazole
20 mg twice daily (half an hour before breakfast and din-
ner) is given for the initial four weeks. The patients are
reassessed and checked for compliance, symptoms, and
adverse events initially at week 4. The dosage is tailored in
a step down manner according to patient satisfaction and/
or symptoms following a set protocol (Figure 3). Then,
the patients are followed every twelve weeks either in per-
son at the office or via telephone, until endpoints are
achieved. Thereafter, the patients are followed as neces-
sary or at least every 6 months for 10 years.
Helicobacter Pylori (HP), if present, is eradicated only if
there is a clear indication for it (i.e. duodenal or gastric
ulcer or erosions, family history of gastric cancer or
patient's preference for HP to be eradicated).
During the initial healing phase, the study medication is
the only acid-suppressing drug to be administered. Other
medications considered necessary for the patient's safety
and well-being can be used or continued.
Follow up
At the base line visit, a pamphlet containing life style
modifications considered appropriate for GERD is given
to the patients in addition to detailed verbal explanation.
Patients are followed at regular three month intervals. If
patients do not show up for two weeks or more after a
scheduled visit, they are contacted by phone. In each fol-
low up, clinical questionnaire will be filled out again.
Patient's weight and drug consumption including PPI and
other drugs are asked. All patients are planned to be fol-
lowed for 10 years.
Table 1: Major and minor symptoms of GERD
Major Minor
HeartBurn (HB) Chronic interscapular pain
Acid Regurgitation (AR) Halitosis
Dysphagia (D) Bitter mouth
Non Cardiac Chest Pain (NCCP) Water brash
Anorexia
Nausea
Hoarseness
Globbus sensation
Chronic cough
Sore throat/mouth
Belching
Table 2: Exclusion Criteria
Esophageal varices
Pregnancy
Advanced cardiovascular disease
History of upper GI surgery
Esophageal or gastric cancer
Using H2 blocker and/or PPIs during the last 2 weeks*
*: These patients were eligible if erosions were seen on endoscopy.BMC Gastroenterology 2007, 7:42 http://www.biomedcentral.com/1471-230X/7/42
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Outcomes and outcome measures
Quality of life is measured with the disease-specific "Qual-
ity of Life in Reflux and Dyspepsia" questionnaire (QOL-
RAD) that is specifically developed and validated to assess
the impact of heartburn and has been validated in Iran
[25]. Generic QoL is measured using the "Medical Out-
come Study Short Form 36 (SF-36) Health Survey" which
has also been validated in Iran [26].
Primary outcomes of interest include: Complete response
(remission off treatment or remission with maintenance
treatment), partial response, and non-response. At the ini-
tial visit a "General Symptom Score" (GSS) and a "Major
Symptom Score" (MSS) is calculated for each patient
using frequency, intensity, and severity of each symptom
(Table 3 and 4). The GSS ranges from zero to 382.
Patients' response to treatment is defined according to the
general symptom score (GSS) and major symptom score
(MSS) and self satisfaction. Accordingly, patients are cate-
gorized as complete, partial, or non-responders. In each
follow up symptom score reduction ratio is calculated
[Symptom Score Reduction Ratio (SSRR) = (Symptom
scoren – Symptom scoren-1 )/Symptom score n, where "n"
is the number of the last visit]. Complete responders are
those whose major symptom resolves or have occasional
symptoms (less than one episode per week) or have a gen-
eral and major SSRR ≥ 75%. Partial responders are those
who have ≥ one episode of their major symptom per week
and are sub grouped to well and fair groups. Well patients
are those who had general or major SSRR of 50%–74%.
General or major SSRR of Fair subgroup is 25%–49%.
Those who have a less than 25% SSRR are considered as
non-responders. If the patient's medication can not be
decreased on 2 successive visits, he/she is considered to
need long-term maintenance. Anti-reflux surgery is
offered to this subgroup. If symptoms recur at any time
Flow chart of patient enrolment Figure 1
Flow chart of patient enrolment. †: Presence of at least one major symptom with appropriate duration, ‡: Presenting just 
by minor symptoms.
                
Suspicious to GERD‡
Confirmed on endoscopy 
or respond to O test
Willing to 
participate
Taking Blood sample
Endoscopy and biopsies
Start treatment and follow up 
(Figure 3)
Blood sample and biopsy 
during endoscopy
Briefing about the Study and 
offering informed consent
Willing to 
participate
Not willing to 
participate
  Exclude  
Clinical Dx of GERD†
Patients suspicious to GERD
Having exclusion criteria
Yes
Exclude
No
Not suggestive of GERD
Exclude Briefing about the Study and 
offering informed consent
Not willing to 
participate
Exclude
Complete the questionnaires (Demographic and Clinical)BMC Gastroenterology 2007, 7:42 http://www.biomedcentral.com/1471-230X/7/42
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after discontinuation of medications, the patient is re-
assessed clinically, possible risk factor(s) identified and
treatment restarted accordingly.
Data management and statistical analysis
During the follow-up phase all case report forms will be
manually checked for completeness and relevant missing
data will be corrected by additional telephone question-
ing. Data are then transmitted to a data base specifically
designed for this study. The data base is maintained in the
central computer of the GERD study group at the digestive
disease research center of Tehran University of medical
sciences. Statistical calculations are performed using SPSS
16.0 (SPSS Inc., Chicago, IL, USA) and STATA 9.0 (Stata
corp., College Station, Texas). Various statistical tests are
used according to need.
Discussion
We describe the protocol of a prospective cohort study in
patients presenting with GERD related symptoms. This
study will provide important new information on a highly
controversial area of characteristics of different subgroups
of GERD patients and their response to treatment. Though
it is not a randomized trial, we believe a carefully designed
and analyzed cohort study will improve our knowledge of
both treatment efficacy and safety in routine practice. The
primary aim of this study is to better determine the out-
comes of GERD patients as it is practiced today and will
provide useful information on long term follow-up of
these patients. The results may help improve the selection
criteria for medical therapy and even surgery, better define
GERD related symptoms and its spectrum, the prognosis
following therapy, and improve our ability to predict
patients with the most favorable treatment approaches.
Our data show that such a study is feasible and follow-
ups, which are the main concern, can be done at a fairly
reliable way. The results of this study will help to clarify
the course of various subgroups of GERD patients after
coming to medical attention and their response to treat-
ment considering different variables. In addition, the
basic symptoms and biological database will fuel further
molecular epidemiologic studies.
Abbreviations
NERD: Non-Erosive Reflux Disease; ERD: Erosive Reflux
Disease;  BE: Barrett Esophagus; GERD: Gastro-Esopha-
geal Reflux Disease; IBS: Irritable Bowel Syndrome: MES:
Metabolic Syndrome; PUD: Peptic Ulcer Disease; PARSI:
Prospective Acid Reflux Study of Iran; DDRC: Digestive
Disease Research Center; TUMS: Tehran University of
Medical Sciences; RUT: Rapid Urease Test; GI: Gastro-
Places of taking biopsies Figure 2
Places of taking biopsies. A: lower third of esophagus within 2 cm from the z-line, B: Gastroesophageal junction across the 
z-line, C: Cardia, D: Body, E: Antrum.BMC Gastroenterology 2007, 7:42 http://www.biomedcentral.com/1471-230X/7/42
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Therapy flow chart of the study Figure 3
Therapy flow chart of the study. * Whenever the dosage is tailored, patients should assess her/his well being after one 
week. If patient is better with the previous prescription, patient should back to the previous dosage and continue till the next 
visit.
1
Nighttime or early 
morning symptom
Daily Symptom
PPI 20 mg TID PPI 20 mg BID + 
Ranitidine 300 mg 
or Famotidine 40 mg 
QHS
Symptomatic Asymptomatic
PPI 20 mg BID + Ranitidine 300 
mg or Famotidine 40 mg QHS
Symptomatic
Symptomatic
20 mg BID for 
next three month
Reassessment
Overlap with other 
diagnosis (like IBS)
No alarm sign or 
other diagnosis
Reassessment one month later
Nighttime or early 
morning symptom
Daily Symptom
Reassessment one month later
Asymptomatic
Follow every 3 month
Do the specific 
management
Initial therapy with omeprazole 20mg BID for 4 weeks
Asymptomatic Symptomatic
2o mg daily * for next 3 months
Asymptomatic
2o mg QOD * for 
next 3 months
Asymptomatic
Discontinue the drug*
Continue follow up with 3 
months interval till 10 years
Presence of 
alarm signs
20 mg QID + 
Nortryptiline 10 mg QHS
Symptomatic
Treatment failureB
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Table 3: Questions and scores used for evaluating frequency, intensity, and severity of GERD related symptoms
Symptoms Frequency Intensity Severity
Heartburn, Acid 
regurgitation, 
Non Cardiac 
Chest Pain, 
Chronic 
Interscapular Pain
None (0) With specific 
food (1)
Less than weekly 
(2)
1–3 times per 
week (3)
Almost every day 
(4)
Several times a 
day (2×)
Do not feel it if 
don't think about 
it (2)
Feel it, but not 
interfering with 
work and/or daily 
life (3)
Interfering with 
work and/or daily 
life (4)
Halitosis, Water 
Brash, Nausea, 
Hoarseness, 
Globus, Bitter 
Mouth
None (0) Less than weekly 
(1)
1–3 times per 
week (2)
Almost every day 
(3)
Several times a 
day (2×)
Do not feel it if 
don't think about 
it (2)
Feel it, but not 
interfering with 
work and/or daily 
life (3)
Interfering with 
work and/or daily 
life (4)
Dysphagia, 
Odynophagia
None (0) With specific 
food or condition 
(1)
Less than weekly 
(2)
1–3 times per 
week (3)
Almost every day 
(4)
Relieves 
spontaneously 
(2)
Relieved with 
drinking water(3)
Only partially 
relieved by 
ingesting large 
amounts of water 
(4)
Chronic Cough, 
Sore throat and 
mouth
None (0) Occasionally (1) Most days (2) Almost every day 
(3)
Almost all day 
long (2×)
Not interfering 
with work and/or 
daily life (2)
Interfering with 
work and/or daily 
life (3)
Anorexia None (0) Less than 
weekly(1)
1–3 times per 
week (2)
Almost every day 
(3)
Several times a 
day (2×)
Although present 
but I take almost 
normal amount 
of food (2)
I have cut my 
food intake (3)
I am almost 
unable to take 
any food (4)
Belching None (0) With specific 
food or condition 
(1)
Less than weekly 
(2)
1–3 times per 
week (3)
Almost every day 
(4)
Almost all day 
long (2×)
Not interfering 
with work and/or 
daily life (2)
Interfering with 
work and/or daily 
life (3)B
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Table 4: An example of calculating the symptom score. For a 45 years old gentleman presenting with the following symptoms for the past 5 months. The Symptom Scores will 
be calculated as follows:
Symptoms Frequency Intensity Severity
Heartburn None (0) With specific 
food (1)
Less than weekly 
(2)
1–3 times per 
week (3)
Almost every 
day (4)
Several times 
a day (2×)
Do not feel it if 
don't think about it 
(2)
Feel it, but not 
interfering with 
work and/or 
daily life (3)
Interfering with 
work and/or daily 
life (4)
Acid 
regurgitation
None (0) With specific 
food (1)
less than 
weekly (2)
1–3 times per 
week (3)
Almost every 
day (4)
Several times a 
day (2×)
Do not feel it if 
don't think 
about it (2)
Feel it, but not 
interfering with 
work and/or daily 
life (3)
Interfering with 
work and/or daily 
life (4)
Halitosis, None (0) Less than weekly 
(1)
1–3 times per 
week (2)
Almost every 
day (3)
Several times 
a day (2×)
Do not feel it if 
don't think about it 
(2)
Feel it, but not 
interfering with 
work and/or 
daily life (3)
Interfering with 
work and/or daily 
life (4)
Anorexia None (0) Less than weekly 
(1)
1–3 times per 
week (2)
Almost every 
day (3)
Several times a 
day (2×)
Although present 
but I take almost 
normal amount of 
food (2)
I have cut my 
food intake (3)
I am almost unable 
to take any food 
(4)
Belching None (0) With specific 
food or 
condition (1)
Less than weekly 
(2)
1–3 times per 
week (3)
Almost every 
day (4)
Almost all day 
long (2×)
Not interfering 
with work and/
or daily life (2)
Interfering with 
work and/or daily 
life (3)
Heartburn = 3*2*3 = 18
Acid regurgitation = 2*2 = 4
Halitosis = 3*2*3 = 18
Anorexia = 3*3 = 9
Belching = 4*2*2 = 16
General Symptom Score (GSS) = Heartburn + Acid regurgitation + Halitosis + Anorexia + Belching = 18+4+18+9 +16 = 64BMC Gastroenterology 2007, 7:42 http://www.biomedcentral.com/1471-230X/7/42
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Intestinal; HP: Helicobacter Pylori; QOLRAD: Quality of
Life in Reflux and Dyspepsia; GSS: General Symptom
Score; MSS: Major Symptom Score; SSRR: Symptom Score
Reduction Ratio.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
All authors participated in conception, design and acqui-
sition of data. RM and SN-M did all upper GI endoscopies
and Biopsies. MS, and BA were the pathologist. S N-M, H
R, M M, A M, M N, R M, and SM A contribute in analysis
and interpretation of data and revising for important
intellectual content. Final approval of the manuscript for
publishing was done by all the authors.
Acknowledgements
Authors wish to thank Dr. Sh. Khalili, Dr. Sh. Rashtak, Dr. R. Khaleghnejad, 
and Dr. AR Abrishami for their participation in data acquisition. This study 
was supported by the Digestive Disease Research Center (DDRC), Shariati 
Hospital, Medical Sciences/University of Tehran.
References
1. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton U 3rd:
Prevalence and clinical spectrum of gastroesophageal reflux:
a population based study in Olmsted County, Minnesota.
Gastroenterology 1997, 112(5):1448-56.
2. El-Serag HB, Sonnenberg A: Opposing time trends of peptic
ulcer and reflux disease.  Gut 1998, 43(3):327-33.
3. Dent J, El-Serag HB, Wallander M-A, Johansson S: Epidemiology of
gastroesophageal reflux disease: A systematic review.  Gut
2005, 54:710-717.
4. Nasseri-Moghaddam S, Malekzadeh M, Sotoudeh M, Tavangar M,
Azimi K, Sohrabpour AA, Mostadjabi P, Fathi H, Minapoor M: Lower
esophagus in dyspeptic Iranian patients: a prospective study.
J Gastroenterol Hepatol 2003, 18(3):5-21.
5. Nouraie M, Razjouyan H, Assady M, Malekzadeh R, Nasseri-
Moghaddam S: Epidemiology of Gastroesophageal Reflux
Symptoms in Tehran, Iran; a population-based Telephone
Survey.  Arch Iran Med 2007, 10(3):289-294.
6. Wicklund 1K, Glise H: Quality of life in different gastrointesti-
nal conditions.  Eur J Surg Suppl 1998, 582:56-61.
7. Revicki DA, Wood M, Maton PN, Sorensen S: The impact of gas-
troesopgaheal reflux disease, on health-related quality of
life.  Am J Med 1998, 104(3):252-8.
8. Armstrong D: Endoscopic evaluation of gastro-esophageal
reflux disease.  Yale J Biol Med 1999, 72(2–3):93-100.
9. Saidi F, Malekzadeh R, Sotoudeh M, Derakhshan MH, Farahvash MJ,
Yazdanbod A, Merat S, Mikaeli J, R Sotoudehmanesh, Nasseri-Mogh-
adam S, Majidpour A, Arshi S, Abedi-Ardakani B, Yoonessi A, Sadr F,
Sepehr A, Fleischer D, Fahimi S: Endoscopic esophageal cancer
survey in the western part of the Caspian Littoral.  Diseases of
the Esophagus 2002, 15:214-218.
10. Spechler SJ: Epidemiology and natural history of gastro-
oesophageal reflux disease.  Digestion 1992, 51(Suppl 1):24-9.
11. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ: Risk fac-
tors associated with symptoms of gastroesophageal reflux.
Am J Med 1999, 106:642-49.
12. Galmiche JP, Bruley des Varannes S: Symptoms and disease
severity in gastro-oesophageal reflux disease.  Scand J Gastroen-
terol Suppl 1994, 201:62-8. Review
13. Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K,
de Groot G, van Oudvorst A, Dalvag A, Junghard O, Wiklund I: Gas-
tro-oesophageal reflux disease in primary care: an interna-
tional study of different treatment strategies with
omeprazole. International GORD Study Group.  Eur J Gastro-
enterol Hepatol 1998, 10(2):119-24.
14. Gerson LB, Shetler K, Triadafilopoulos G: Prevalence of Barrett's
esophagus in asymptomatic individuals.  Gastroenterology 2002,
123(2):461-7.
15. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ: Acid reflux is a
poor predictor for severity of erosive reflux esophagitis.  Dig
Dis Sci 2002, 47(11):2565-73.
16. Lieberman DA, Oehlke M, Helfand M: Risk factors for Barrett's
esophagus in community-based practice. GORGEconsor-
tium. Gastroenterology Outcomes Research Group in
Endoscopy.  Am J Gastroenterol 1997, 92(8):1293-97.
17. Conio M, Filiberti R, Blanchi S, Ferraris R, Marchi S, Ravelli P, Laper-
tosa G, Iaquinto G, Sablich R, Gusmaroli R, Aste H, Giacosa A:
Gruppo Operativo per lo Studio delle Precancerosi Esofagee
(GOSPE) [Risk factors for Barrett's esophagus: a case-con-
trol study].  Int J Cancer 2002, 97(2):225-29.
18. Cameron AJ, Ott BJ, Payne WS: The incidence of adenocarci-
noma in columnar-lined (Barrett's) esophagus.  N Engl J Med
1985, 313(14):857-859.
19. Eisen G: The epidemiology of gastroesophageal reflux: what
we know and what we need to know.  Am J Gastroenterol 2001,
96(suppl):S16-18.
20. Isolauri J, Luostarinen M, Isolauri E, Reinikainen P, Viljakka M, Keyri-
lainen O: Natural course of gastroesophageal reflux disease:
17–22 year follow-up of 60 patients.  Am J Gastroenterol 1997,
92:37-41.
21. McDougall NI, Johnston BT, Collins JS, McFarland RJ, Love AH:
Three to 4.5 year prospective study of prognostic indicators
in gastrooesophageal reflux disease.  Scand J Gastroenterol 1998,
33:1016-22.
22. Labenz J, Jaspersen D, Kulig M, Leodolter A, Lind T, Meyer-Sabellek
W, Stolte M, Vieth M, Willich S, Malfertheiner P: Risk factors for
erosive esophagitis: a multivariate analysis based on the Pro-
GERD study initiative.  Am J Gastroenterol 2004, 99(9):1652-6.
23. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP,
Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L:
Endoscopic assessment of oesophagitis: clinical and func-
tional correlates and further validation of the Los Angeles
classification.  Gut 1999, 45(2):172-80.
24. Dixon MF, Genta RM, Yardley JH, Correa P: Classification and
grading of gastritis. The updated Sydney System. Interna-
tional Workshop on the Histopathology of Gastritis, Hou-
ston 1994.  Am J Surg Pathol 1996, 20(10):1161-81. Review
25. Tofangchiha S, Razjouyan H, Ghotbi MH, Nouraie M, Alimohammadi
M, Mamarabadi M, Nasrollahzadeh D, Didar L, Mofid A, Malekzadeh
R, Nasseri-Moghaddam S: Validation of the Quality of Life In
Reflux and Dyspepsia (QOLRAD) Questionnaire in Patients
with Iranian patients with GERD [abstract].  Govaresh 2006,
11:s28.
26. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B: The Short
Form Health Survey (SF-36): translation and validation
study of the Iranian version.  Qual Life Res 2005, 14:875-882.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-230X/7/42/pre
pub